|Videos|July 15, 2021
Treatment-Resistant Depression: Financial Support for Esketamine Therapy
Advertisement
Episodes in this series
Recommendations that can help clinicians navigate through the reimbursement process and best support patients who receive intranasal esketamine for treatment-resistant depression.
Advertisement
Related to this article
Lisa Harding, MD, urges psychiatrists to gather histories, deprescribe safely, and send focused sleep referrals now that orexin agonists have arrived for narcolepsy.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Explore PTSD prevalence, comorbidities, and first-line care as we invite clinicians to share cases and research.
Veterans younger than 30 starting antidepressants, and anyone coprescribed opioids and benzodiazepines, will need to sign consent forms starting in 2027.
How genes and early stress interact to shape antisocial behavior, from dopamine and serotonin pathways to MAOA and oxytocin findings.
Policy shifts have opened the door to telehealth buprenorphine for pregnant and postpartum women with OUD, but research, guidelines, and state policy lag behind.
Overlooking how hearing loss and sign language shape the Mental Status Examination can make language deprivation look like psychosis, authors warn.
Advertisement
Advertisement
Trending on Psychiatric Times
1
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
2
From Side Effect to Target: Rethinking Metabolic Dysfunction in Psychiatry
3
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
4
Hippocampal Generative Processes During Sleep Support Rapid Learning of New Associations
5